ARISTOCORT
LOE ApproachingNDAORALSYRUP
Approved
Sep 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARISTOCORT is an oral syrup formulation of a small-molecule corticosteroid approved in 1959 by Astellas. The drug's specific mechanism of action and approved indications are not detailed in available data, but as a legacy corticosteroid it likely treats inflammatory and immune-mediated conditions. This is a mature, well-established product with decades of clinical use.
LOE Approaching
With LOE approaching, this mature product likely operates with a lean, efficiency-focused commercial team focused on managed care and compliance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ARISTOCORT offers limited career growth opportunity given its LOE-approaching status and zero linked open positions. Assignment to this product typically involves mature market management, compliance optimization, and stakeholder retention rather than innovation or expansion.
Brand ManagerProduct Manager
Worked on ARISTOCORT at Astellas? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.